Over the last decade, chronic critical illness (CCI) has emerged as an epidemic in intensive care unit (ICU) survivors worldwide. Advances in ICU technology and implementation of evidence-based care bundles have significantly decreased early deaths and have allowed patients to survive previously lethal multiple organ failure (MOF). Many MOF survivors, however, experience a persistent dysregulated immune response that is causing an increasingly predominant clinical phenotype called the persistent inflammation, immunosuppression, and catabolism syndrome (PICS). The elderly are especially vulnerable; thus, as the population ages the prevalence of this CCI/PICS clinical trajectory will undoubtedly grow. Unfortunately, there are no proven therapies to prevent PICS, and multimodality interventions will be required. The purpose of this review is to: (1) discuss CCI as it relates to PICS, (2) identify the burden on healthcare and poor outcomes of these patients, and (3) describe possible nutrition interventions for the CCI/PICS phenotype. (Nutr Clin Pract. 2018;33:39-45) 
Introduction
Critical illness phenotypes continue to evolve as mortality from acute critical illness has dramatically decreased, especially when discussing severe sepsis and septic shock. 1, 2 Nevertheless, patients who survive the acute phase of critical illness continue to linger much longer in the intensive care unit (ICU), developing a much more chronic phase. The term chronic critical illness (CCI) was first coined by Girard and Raffin 3 in 1985 when discussing acutely ill patients requiring ongoing support in the ICU setting. In the late 1990s, reports continuing to describe CCI emerged under a variety of descriptive terms, including "neuropathy of critical illness," "myopathy of critical illness," "ICU acquired weakness," and most recently, "post intensive care unit syndrome." 4 These reports largely originated from medical ICUs and included a rather heterogeneous mixture of admission diagnoses. A common thread among most reports describing CCI seemed to have an acute exacerbation of chronic diseases and need for prolonged mechanical ventilation. Thus, persistent low-grade organ dysfunction appears to be a common thread linking most causative factors of CCI.
A clinical definition of CCI as a prolonged mechanical ventilation support for >21 days for at least 6 h/day or patients who require tracheostomy within the course of their ICU admission was described in 2005. 5 Kahn and colleagues 6 used a combined quantitative and qualitative measure to define CCI: >8 days in an ICU with 1 of 6 eligible clinical conditions (prolonged acute mechanical ventilation, tracheotomy, stroke, traumatic brain injury, sepsis, or severe wounds). In the search to define persistent inflammation, immunosuppression, and catabolism syndrome (PICS), Vanzant et al 7 defined CCI as >14 days in ICU with organ dysfunction. CCI and PICS both represent patients with aberrant immunology where homeostasis is not achieved and dysfunction persists. These patients with CCI experience ongoing immunosuppression (eg, lymphopenia), inflammation (eg, neutrophilia with elevated acute-phase response proteins), and significant lean muscle mass wasting associated with catabolism.
Unfortunately, PICS is the consequence of optimal evidence-based ICU care, and currently the therapies to prevent or treat CCI and PICS are limited. Given the complex and persistent nature of the underlying dysregulated immunity, multimodality treatment will be required that will need to be extended beyond hospitalization to enhance rehabilitation. The purpose of this review is to: (1) discuss CCI as it relates to PICS, (2) identify the burden on healthcare and poor outcomes of these patients, and (3) describe possible nutrition interventions for the CCI/PICS phenotype.
The CCI/PICS Clinical Trajectory
CCI, as discussed earlier, is organ dysfunction that persists >14 days in an ICU patient. This is surprisingly common in surgical ICUs. Originally, it was thought that the leading risk for CCI was age >65 years, chronic comorbidities, and admission to the ICU. [7] [8] [9] Recently, in accordance with previous thoughts, new evidence suggests that after major torso trauma, CCI occurs in roughly 20%, whereas after sepsis the incidence rate approaches 50%. 11, 12 These patients with CCI compared with patients who rapidly recover are typically older (>55 years), have poorer premorbid health status, and have sustained more severe trauma or septic insults.
7,13-17 Mira, Brakenridge, and colleauges 11 concluded that CCI is a common trajectory of critically ill polytrauma survivors and is associated with poor long-term outcomes. In this recent review of patients with major torso trauma, the multivariate analysis revealed age ࣙ55 years, systolic hypotension ࣘ70 mm Hg, transfusion ࣙ5 units packed red blood cells within 24 hours, and Denver multiple organ failure (MOF) score at 72 hours as independent predictors of CCI (area under the curve 0.87, 95% CI: 0.75, 0.95). 11 In contrast, a recent review of surgical patients with sepsis revealed that of the 145 patients with sepsis who were enrolled, 19 (13%) died during their hospitalization and 71 (49%) experienced development of CCI based on the definition of CCI as >14-day ICU length of stay and persistent organ dysfunction. 12 Several other ICU pathophysiologic states are either similar in nature or are part of the CCI spectrum. Among these entities are ICU-acquired weakness (ICUAW), diaphragm dysfunction associated with prolonged mechanical ventilation, and PICS. 10 Most of these patients, if not all, were observed to lose tremendous amounts of lean body mass despite optimal nutrition, causing profound weakness (catabolism), suffer from recurrent nosocomial infections (immunosuppression), typically develop decubitus ulcers, have poor wound healing, have sepsis recidivism, and ultimately experience poor long-term outcomes. [8] [9] [10] 18 A recent report by Puthucheary et al 19 demonstrated the basis of ICUAW associated with CCI. In this prospective observation trial of 63 critically ill patients with an average APACHE II (Acute Physiology and Chronic Health Evaluation II) score of 23.5, the authors found that the rectus femoris cross-sectional area (CSA) decreased on average 17.7% by day 10, and the ratio of protein to DNA decreased by 29.5%. 19 They also observed that with increasing organ failure the muscle breakdown and decrease in CSA were more significant despite adequate nutrition. In fact, "leg protein breakdown remained elevated throughout the study with the pattern of intracellular signaling supporting increased breakdown and decreased synthesis." 19 The novel observation of the study was that 40% of these patients had evidence of muscle necrosis associated with inflammatory cell infiltrate on serial muscle biopsies. This provocative observation indicated that the muscle is likely a target of the dysregulated immunity related to CCI/PICS and may explain why early, aggressive nutrition may be ineffective in preventing the progressive muscle loss seen in these patients. 19 In addition, patients with CCI tend to be or become frail and suffer from significant levels of pain, dyspnea, psychological distress, thirst, fatigue, delirium, and distress related to impaired communication. [20] [21] [22] [23] [24] [25] These symptoms not only stem from the protracted course of their hospital stay, but are associated with their exposure to ICU interventions that cause distressing symptoms as well. 20, 21, 24, 26 Ultimately, patients with CCI and PICS have poor long-term quality of life; suffering from depression, cognitive impairment, complex physiologic abnormalities, organ dysfunction, neuroendocrine deficits, and immunologic dysfunction. 13, 14, 24, [27] [28] [29] [30] [31] [32] Although the underlying mechanism for these devastating ICU syndromes is undoubtedly multifactorial, the laboratory work of Moldawer, Efron, and colleagues 33 using chronic murine models of sepsis and trauma have identified the expansion of myeloid-derived suppressor cells (MDSCs) to explain the persistent immune dysregulation observed in CCI/PICS. A recent focused translational study of 67 surgical patients with severe sepsis confirmed the clinical relevance of these laboratory observations. It showed that the numbers of MDSCs rapidly increase after sepsis and are persistently elevated out to 28 days. 33 Importantly, these MDSCs were shown to suppress T lymphocyte proliferation and decrease the release of T H1 and T H2 cytokines. Moreover, MDSC expansion correlated with adverse outcomes including: (1) early increased expansion was associated with early mortality, (2) persistent expansion was associated with prolonged ICU stays, and (3) persistent expansion was a strong independent predictor of nosocomial infections and poor postdischarge disposition. 33 These data provide the theoretical basis for the use of immune stimulants that modulate MDCSs similar to what has been successfully utilized in advanced malignancies to achieve durable response rates.
Burden on Healthcare and Poor Outcomes
Now that patients with CCI/PICS are surviving and being discharged from ICUs, healthcare costs reflect this struggling patient population and places significant burden on their caretakers. In fact, Kahn et al 6, 34 estimated that 5%-7.6% of patients admitted to the ICU experience CCI, accounting for >380,000 cases, 107,000 in-hospital deaths, and >$26 billion in healthcare expenses. Iwashyna et al 35 also demonstrated that despite CCI accounting for only 5% of ICU admissions, patients that experience development of CCI have >30% of ICU utilization. Both authors report that these patients are less likely to be discharged home and have higher inpatient mortality. 6, 35 In fact, of the patients who ultimately experience CCI, Cox et al 36 found that only 10% will achieve enough functional capacity to independently live at home within 1 year of discharge.
In new data discussed earlier, Mira, Brakenridge, and colleagues 11 demonstrate that CCI patients are more likely to be discharged to a long-term care setting (56% vs 34%; P = 0.008) than to a rehabilitation facility or home. In addition, patients with CCI at 4 months had higher mortality rates (16.0% vs 1.9%; P < 0.05) compared with survivors scoring lower in general health measures (P < 0.005). 11 In another recent report, patients with CCI were more likely to be discharged to long-term acute care facilities (32% vs 3%; P < 0.0001), whereas those with rapid recovery were more often discharged to home. The 6-month mortality rate was significantly higher in CCI as compared with a rapid recovery cohort (37% vs 2%; P < 0.01).
12 These 2 studies only affirm that patients with CCI have reduced rehabilitation potential and poor discharge disposition.
Ultimately, these patients with CCI live through the acute illness only to have an exuberant financial toll on healthcare systems 13, 34, 37 and caregivers (strained relationships, depressed mood, adverse psychological responses, and underlying stress). 38, 39 To revisit Kahn et al, 6 these authors published that the in-hospital mortality rate for a patient with CCI was 30.9%, and that the overall population-based prevalence was 34.4 per 100,000. Extrapolating these data to the entire United States, for the year 2009, Kahn et al 6 estimated a total of 380,001 cases of CCI, 107,880 in-hospital deaths, and $26 billion in hospital-related costs.
The U.S. Census Bureau estimates that between 2000 and 2025 the elderly population will grow by ß80%; thus, the incidence of CCI and PICS are likely increase as well. 40 Thus, a P50 grant award to the University of Florida, Health Sepsis and Critical Illness Research Center (UF SCIRC) will continue to research CCI, frailty in surgery, and PICS through the grant by NIGMS entitled, "PICS: A New Horizon for Surgical Critical Care".
Possible Nutrition Interventions
The persistent smoldering inflammatory and catabolic state, hormonal elaboration, and perpetual downward spiral of CCI produce a "cachexia" phenotype for which current ICU nutrition interventions are relatively ineffective. Current literature surrounding supportive care for patients with CCI is unified by 2 crucial strategies: early mobilization and anabolic nutrition. In this section, the role of protein and anabolic supplements, immunonutrition, and specialized pro-resolving mediators (SPMs) will be reviewed.
Protein and Anabolic Supplements
In reviewing the literature on sarcopenia, a slower, yet similar pathologic state to CCI, Fiatarone et al [41] [42] [43] recommended resistance exercise and anabolic nutrition. The authors stressed the need for high-resistance exercise (early mobilization of ICU patients) coupled with supplemental nutrition to maintain lean muscle mass. Reinforcing Fiatarone's claim, Paddon-Jones et al [44] [45] [46] established that daily protein consumption of 0.8-1.5 g/kg/d of daily protein and dietary-derived amino acids (AAs) potentially slows or prevents muscle protein catabolism. In addition, Morley et al and the Society for Sarcopenia, Cachexia, and Wasting Disease 47 recommended >1.5 g/kg/d of protein, as well as in combination with exercise and supplemental leucine and creatine. Leucine is an AA that can stimulate the mammalian target of rapamycin (mTOR) pathway, increase protein synthesis, and inhibit protein breakdown.
More recently, however, The Protein Summit met to reestablish new recommendations for nutrition guidelines. Historically, critically ill patients were recommended to receive >1.2 g/kg/d protein supplementation. 8, 48, 49 As the literature evolves, an understanding has emerged that the old recommendation may be underfeeding protein. During periods of physiologic stress, the body tends to catabolize large amounts of protein. 50 In sepsis and blunt trauma, Plank, Monk, and colleagues [51] [52] [53] showed that resting energy expenditure peaks at about 4-5 days, can continue for up to 12 days, and can lose up to 16% of total body protein.
Similarly, in burn patients, "the hypermetabolic response to major burn injury is associated with increased energy expenditure, insulin resistance, immunodeficiency, and whole body catabolism that persists for months after injury." 54 This has led Herndon and Tompkins 55 to recommend 2 g/kg/d protein supplementation for appropriate compensation of the catabolic insult. Nevertheless, the current guidelines have raised the recommendation to >1.5 g/kg/d protein supplementation to provide adequate nutrients for the critically ill, catabolic patient. However, the following question remains: Is 1.5 g/kg/d enough for patients with CCI?
Starting around 2010, studies have emerged showing clear benefit to delivery of protein calories over nonprotein supplements. Weijs et al 49, 56 showed that early high-protein delivery had survival benefit, yet energy overfeeding was linked to increased mortality. Allingstrup et al 57 echoed Weijs et al's 49, 56 findings, adding that a higher provision of protein (>1.46 g/kg/d vs 1.06 or 0.79 g/kg/d) and AAs was associated with lower mortality.
Importantly, Compher et al 58 showed that increased protein delivery had a significant survival benefit in nutritionally high-risk patients based off the Nutrition Risk in the Critically Ill (NUTRIC) score >5. Compher et al 58 concluded that greater nutrition and protein intake is associated with lower mortality and faster time to discharge alive in the high-risk, longer-stay patients, but not significantly so in nutritionally low-risk patients. These are the patients with CCI. The ones who "are high risk and longer stay patients." Moreover, in 2013, Deutz and Wolfe 59 described an "anabolic response" where higher protein supplementation suppresses endogenous protein breakdown. The anabolic response is a measure of fractional synthetic rate minus the protein breakdown, and it was even more positive with higher amounts of protein provided. 59 This has inordinate implications for patients with CCI/PICS to combat catabolism and potentially feed them with increasing doses of protein. Unfortunately, there is a paucity of literature prescribing large doses of protein in the CCI/PICS patient population, and at this time only inferences can be made based on the body of literature we currently have.
In addition to protein delivery, there are increasing supplements that intensivists could provide to help trigger anabolism or use as an anticatabolism agent. Among these agents, Herndon et al 54, [60] [61] [62] [63] [64] [65] described in the pediatric burn population the use of: (1) 64 and (5) exercise programs. 65 These hormones and medications have a net ability to be "potent anabolic agent and salutary modulator of posttraumatic metabolic responses." 54 The conclusion was that they can increase lean muscle mass, bone mineralization, and strength, and attenuate the hypermetabolic response to burn. In doing so, patients would have shortened recovery. 60, 61, 66 Immunonutrition Protein and AAs are not only beneficial for this patient population, but also are intriguing because they can serve a dual purpose with the capability for immunomodulation. Arginine is a conditional AA whereby endogenous production is insufficient during periods of metabolic stress (such as sepsis) and requires supplementation to restore maximal function of the immune system. 67 With regard to the immune system, arginine has 2 important roles: production of nitric oxide (NO) and lymphocyte function.
Three isoforms of NO synthase (endothelial, inducible, and neuronal) transform arginine into systemic NO. 8, [68] [69] [70] [71] [72] [73] [74] [75] [76] NO has been shown to be an intracellular signaling molecule, influencing a multitude of mammalian organ systems. NO is also responsible for improved bactericidal action in macrophages. Arginine also has a potent modulatory role on the immune system via its effects on lymphocyte proliferation and maturation, as well as lymphocyte and macrophage differentiation. [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] Thus, arginine deficiency or unavailability leads to T lymphocyte suppression and lack of proliferation. 77, 80, 83 Consequently, T cell dysfunction leads to reduced circulating CD4 cells, increased interleukin-2, increased interferon-γ production, and loss of T cell receptor complex called the ζ -chain peptide rending the receptor incapable of recognizing antigen. 67, 69, 83, 87 Limited arginine coupled with a loss of T cell receptor function results in multilevel impaired immune function and response. This immune incompetence is believed to contribute to an increased infectious morbidity in critically ill patients. 83 Controversy exists as to the supplementation of arginine during sepsis, but the patients with CCI/PICS are typically outside their initial septic insult. Thus, theoretical benefit would be derived by repleting this conditional AA in this patient population to restore some of the immunosuppression.
Specialized Pro-Resolving Mediators
A relatively new agent that shows promise in treating and preventing CCI is fat mediators collectively called SPMs, of which resolvins have the most potential. SPMs are purified fish oil that promote resolution of the aberrant inflammatory cascade. Serhan et al 88, 89 identified that SPMs decrease inflammation by cessation of leukocyte infiltration and activation, and "pro-resolve" inflammation through enhanced macrophage clearance of debris, bacteria, and apoptotic cells. Further research is needed, but these molecules could potentially attenuate the systemic inflammatory response syndrome/septic response, allowing for early recovery back to functional status in our critically ill patient population.
Conclusion
CCI is a pathophysiologic state, much like PICS, that is very difficult to treat. Identifying who is going to acquire CCI is of utmost importance to starting various therapeutic strategies early to hopefully stop the potentiation to PICS. Breaking this downward spiral is going to take a multimodal approach combating the malnutrition and ICUAW/neuropathy and restoring anabolism. Further research is needed at the cellular level to control MDSC proliferation, and in the outcomes arena to clinically determine which nutrition strategies have impact. High-protein supplementation has been shown to work, but now we need to determine how much is best for patient with CCI. Finally, SPMs could hold the future for attenuating the overly robust and persistent immunosuppressive, inflammatory, catabolic nature patients with CCI have with the ultimate goal to regain muscle mass, increase the possibility of rehabilitation, and regain baseline function/independence once discharged from the ICU.
